Placental Hormone Withdrawal at Delivery
Delivery of the placenta abruptly ends pregnancy-related insulin resistance.
- hPL: Key hormone drop (Placental lactogen removed)
- Minutes: Onset (After placental delivery)
- ↓ Sharp: Insulin resistance (Rapid reversal begins)
- ~7%: GDM prevalence (Of pregnancies (illustrative))
Mechanism of hormone withdrawal
Placenta removal ends hPL, progesterone, and cortisol-driven resistance.
Placeholder: hormone clearance drives rapid metabolic shift postpartum.
Glucose Normalization Within Days
Maternal glycemia typically returns toward normal within days after birth.
- 1–3 days: Normalization window (Typical postpartum course)
- ↓ Fast: Insulin needs (Often below pre-pregnancy levels)
- ~10–15%: Persistent hyperglycemia (Illustrative fraction)
- Fasting glucose: Monitoring (Inpatient check)
Early postpartum glucose course
Placeholder: glucose curve trends down toward the normal band quickly.
Placeholder: most patients normalize before hospital discharge.
6-Week Postpartum OGTT Retest
A 75g oral glucose tolerance test at 6 weeks reclassifies glucose status.
- 6 weeks: Test timing (Postpartum standard)
- 75g OGTT: Test type (2-hour test)
- ~15–20%: Abnormal result (Illustrative rate)
- ~2–5%: Reclassified as T2D (Illustrative rate)
Purpose of the retest
Placeholder: the 6-week OGTT distinguishes normal, prediabetes, and diabetes.
Placeholder: early retest catches persistent glucose abnormality.
Long-Term Type 2 Diabetes Risk
Cumulative type 2 diabetes risk after GDM can reach up to about 50%.
- Up to 50%: 10-year cumulative risk (Illustrative ceiling)
- ~7–10×: Risk vs. no GDM (Relative risk, illustrative)
- 5–10 yrs: Peak risk window (Post-pregnancy)
- ~30–50%: Lifestyle mitigation (Illustrative reduction)
Trajectory of long-term risk
Placeholder: risk climbs steadily over years without intervention.
Placeholder: adherence to lifestyle change meaningfully lowers risk.
Annual Screening Recommendation
Annual or periodic glucose screening is recommended for years after GDM.
- Annual: Recommended interval (Or every 1–3 years)
- FPG/A1c/OGTT: Test options (Clinician choice)
- Lifelong: Duration (Ongoing monitoring)
- Diet + exercise: Counseling (Standard advice)
Screening cadence guidance
Placeholder: regular screening enables earlier detection and intervention.
Placeholder: annual screening plus lifestyle change is the core recommendation.